Status:
SUSPENDED
Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma
Lead Sponsor:
Weill Medical College of Cornell University
Collaborating Sponsors:
William Rhodes Center for Glioblastoma
Conditions:
Glioma
Eligibility:
All Genders
18-100 years
Phase:
PHASE1
Brief Summary
This is a pilot study to assess a new methodology developed for High Grade Glioma (HGG). FMISO PET (Fluoromisonidazole-PET) allows researchers to study whether tumor cells lack oxygen (hypoxia). FLT P...
Detailed Description
This is a pilot study to assess a novel methodology recently developed to simultaneously image tumor hypoxia and proliferation by means of simultaneous FMISO and FLT PET acquisition. FMISO (18F-Fluoro...
Eligibility Criteria
Inclusion
- Male or female ≥ 18 years of age
- Documentation of a suspected HGG diagnosis based on clinical and MRI findings
Exclusion
- Pregnant or breastfeeding
- Contraindications to receiving Positron Emission Tomography (PET) imaging (e.g. claustrophobia)
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2025
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04309552
Start Date
February 1 2021
End Date
November 1 2025
Last Update
June 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Weill Cornell Medical College
New York, New York, United States, 10021